Northern Trust’s Rein Therapeutics RNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$83.4K Buy
64,136
+23,667
+58% +$29.4K ﹤0.01% 4144
2025
Q4
$46.9K Buy
40,469
+14,706
+57% +$20.3K ﹤0.01% 4291
2025
Q3
$29.5K Hold
25,763
﹤0.01% 4342
2025
Q2
$36.1K Hold
25,763
﹤0.01% 4282
2025
Q1
$45.6K Hold
25,763
﹤0.01% 4242
2024
Q4
$59.3K Hold
25,763
﹤0.01% 4243
2024
Q3
$91.2K Hold
25,763
﹤0.01% 4080
2024
Q2
$71.4K Buy
+25,763
New +$106K ﹤0.01% 4128
2022
Q4
Sell
-5,690
Closed -$24K 4718
2022
Q3
$24K Hold
5,690
﹤0.01% 4516
2022
Q2
$30K Sell
5,690
-704
-11% -$6.47K ﹤0.01% 4557
2022
Q1
$65K Hold
6,394
﹤0.01% 4473
2021
Q4
$72K Hold
6,394
﹤0.01% 4517
2021
Q3
$130K Hold
6,394
﹤0.01% 4333
2021
Q2
$160K Hold
6,394
﹤0.01% 4230
2021
Q1
$183K Buy
6,394
+5,056
+378% +$173K ﹤0.01% 4140
2020
Q4
$28K Hold
1,338
﹤0.01% 4298
2020
Q3
$35K Buy
+1,338
New +$31.5K ﹤0.01% 4145
2018
Q2
Sell
-906
Closed -$147K 4334
2018
Q1
$147K Buy
906
+22
+2% +$3.92K ﹤0.01% 3886
2017
Q4
$186K Sell
884
-67
-7% -$16.1K ﹤0.01% 3837
2017
Q3
$254K Buy
+951
New +$239K ﹤0.01% 3723

Other funds holding RNTX

Northern Trust's RNTX Position: Q1 2026 in Review

Northern Trust increased its Rein Therapeutics (RNTX) stake by 58% in Q1 2026, buying an estimated $29.4K and bringing the position to 64,136 shares worth $83.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4144.

Northern Trust first reported a position in RNTX in Q3 2017 and has held it in 20 quarters since. The position peaked at $254K in Q3 2017. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Northern Trust held 64,136 shares of Rein Therapeutics worth $83.4K as of Q1 2026.
  • Northern Trust bought 23,667 Rein Therapeutics shares in Q1 2026, an estimated $29.4K.
  • Rein Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4144 holding.
  • Northern Trust first reported a position in Rein Therapeutics in Q3 2017 and has held it in 20 quarters since.
  • Northern Trust's Rein Therapeutics position peaked at $254K in Q3 2017.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.